Giant subependymoma developed in a patient with aniridia: Analyses of PAX6 and tumor-relevant genes

Motoko Maekawa, Hironori Fujisawa, Yoshimi Iwayama, Akira Tamase, Tomoko Toyota, Noriko Osumi, Takeo Yoshikawa

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


We observed an unusually large subependymoma in a female patient with congenital aniridia. To analyze the genetic mechanisms of tumorigenesis, we first examined the paired box 6 (PAX6) gene using both tumor tissue and peripheral lymphocytes. Tumor suppressor activity has been proposed for PAX6 in gliomas, in addition to its well-known role in the eye development. Using genomic quantitative PCR and loss of heterozygosity analysis, we identified hemizygous deletions in the 5'-region of PAX6. In lymphocytes, the deletion within PAX6 spanned from between exons 6 and 7 to the 5'-upstream region of the gene, but did not reach the upstream gene, RNC1, which is reported to be associated with tumors. The subependymoma had an additional de novo deletion spanning from the intron 4 to intron 6 of PAX6, although we could not completely determine whether these two deletions are on the same chromosome or not. We also examined other potentially relevant tumor suppressor genes: PTEN, TP53 and SOX2. However, we detected no exonic mutations or deletions in these genes. Collectively, we speculate that the defect in PAX6 may have contributed to the extremely large size of the subependymoma, due to a loss of tumor suppressor activity in glial cell lineage.

Original languageEnglish
Pages (from-to)1033-1041
Number of pages9
JournalBrain Pathology
Issue number6
Publication statusPublished - 2010 Nov


  • PAX6 deletion
  • PTEN
  • SOX2
  • TP53
  • genomic quantitative PCR
  • loss of heterozygosity


Dive into the research topics of 'Giant subependymoma developed in a patient with aniridia: Analyses of PAX6 and tumor-relevant genes'. Together they form a unique fingerprint.

Cite this